DPI Formulation Development and Manufacturing

The respiratory system provides an attractive drug-absorption target to treat local and systemic diseases and is increasingly used to deliver small molecules and biotherapeutics. As described in this technical brief, Lonza has extensive experience in formulation development and manufacturing of respiratory drug-delivery products from proof of concept (POC) to manufacturing of dry-powder inhalation (DPI) formulations. Capabilities include optimized particle engineering, precision micro-dosing, rapid screening, clinically relevant testing, and Good Manufacturing Practice (GMP) production. To learn more, please read our technical brief.